Supporting this idea, drugs designed to degrade mutant TP53, including 17-AAG (HSP90 inhibitor) and SAHA (histone deacetylase inhibitor), effectively reduce the invasiveness of grafted tumours of MDA-MB-468 cells carrying the TP53R273H mutation in mouse xenograft models.71 Taken together, the results presented here can potentially be used to explore novel therapeutic options for cancer patients carrying mutant TP53. This evidence concerns the gene TP53 and cancer.